News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sankyo Company, Ltd. (SKXOF.PK) To Launch Osteoporosis Treatment Drug In Europe


7/19/2006 2:19:19 PM

Tokyo, July 19, 2006 (JCN) - Daiichi Sankyo Europe GmbH, a wholly owned subsidiary of Sankyo Co. Ltd., have agreed with Eli Lilly on the launch of EVISTA (raloxifene), a new drug that helps prevent osteoporosis and can only be taken after menopause. Raloxifene is a selective estrogen receptor modulator, specifically developed to maintain beneficial estrogenic activity on bone and lipids and antiestrogenic activity on endometrial and breast tissue.

Read at JCN Newswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES